Diagnostics

Precede Biosciences' epigenomic blood test predicts radioligand therapy resistance, opening doors for targeted post-PSMA treatments in advanced prostate cancer.

RIVANNA's newly FDA-cleared BoneEnhance software brings AI-driven 3D anatomical mapping to the ER, promising to reshape how we triage musculoskeletal injuries.

Antogen’s new Oklahoma City lab marks a critical pivot from R&D to revenue, proving that scaling complex biotech no longer requires a coastal zip code.

As healthcare costs surge, Americans are rerouting to a decentralized network of at-home tests and supplements. But who truly profits from DIY wellness?

A $1M investment in Geneticure aims to eliminate the guesswork in treating resistant hypertension while anchoring Arizona's growing life sciences corridor.

As traditional imaging gives way to ultrasensitive genomic data, Personalis is poised to disrupt the multi-billion dollar minimal residual disease market.

Hologic and Inpeco's new European partnership signals a strategic shift in medtech, favoring open-architecture automation over closed vendor lock-in.

Metabolic Supply Group is embedding lab testing into its platform, aiming to shift the cash-pay wellness market from prescription mills to data-driven care.

As sub-Saharan Africa battles a severe cervical cancer crisis, offline edge AI is stepping in where traditional labs fall short to bridge the diagnostic divide.

Elephas Biosciences' live-tissue platform achieves 93% accuracy in predicting immunotherapy response, paving a lucrative path for functional precision oncology.

SpotitEarly's Bio-AI platform combines canine scent detection with machine learning to spot early-stage cancer. Will regulatory hurdles stall its 2027 launch?

CellTivity Scientific's Van Gogh system hits a major milestone, proving that real-time metabolic imaging is shifting from a niche tool to a surgical standard.

As new MASH therapeutics hit the market, a strategic partnership between Echosens and Gastro Health signals a lucrative shift from liver biopsies to non-invasive, data-driven diagnostics.

ROSE launches a comprehensive home water test targeting the exposome. But does consumer diagnostics solve our water crisis or just monetize the panic?

Brainomix and the PFF are turning complex AI imaging into actionable patient insights, signaling a major shift in the $15.7B antifibrotic market.

A new alliance between GCCL and LabConnect reveals how independent central labs are building global networks to challenge mega-CROs in clinical trial logistics.

As Fellow Health prepares to present at ASRM 2026, massive datasets from at-home sperm testing expose new links to environmental and systemic wellness.

Digital fitness enters the clinic. Future's new partnership with BodySpec bundles medical-grade DEXA scans to merge remote coaching with physical diagnostics.

As new clinical data debuts at CNS 2026, the intersection of advanced multi-omic tools and state Medicaid policy signals a new era for pediatric care.

As iMDx prepares for the BTIG Kidney Health Forum, the diagnostics challenger is leveraging European clinical data to disrupt the post-transplant testing market.